In addition, TET2 mutation was more frequent in AML patients with normal karyotype according to two studies [25, 30], and there was only one study showing the close association between mutant TET2 and intermediate-risk cytogenetics (Additional file 3: Table S3) [25]. The gene discussed is TET2; the disease is acute myeloid leukemia.